Olympus (7733) AI Stock Analysis

• Market Cap: $2.07T
• Dividend Yield: 1.04%
• Average Volume (3M): 3.80M
• Price to Earnings (P/E): 18.6
• Beta (1Y): 0.74
• Revenue Growth: 0.59%
• EPS Growth: 557.87%
• Country: JP
• Employees: 28,838
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 7.97
• Shares Outstanding: 1,139,116,300
• 10 Day Avg. Volume: 3,441,580
• 30 Day Avg. Volume: 3,803,123
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.95
• Enterprise Value/Revenue: 2.03
• Enterprise Value/Gross Profit: 2.97
• Enterprise Value/Ebitda: 9.00
• 1Y Price Target: $1,922.31
• Price Target Upside: >-0.01% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

• Rating: 71 Outperform
• Price Target: ¥2,088.00 ▲(8.61% Upside)

Olympus scores well due to strong financial performance and positive technical indicators. The company's stable balance sheet and efficient cost management are significant strengths. However, challenges in revenue growth and free cash flow generation, along with a moderate valuation, slightly temper the overall score.

Olympus Business Overview & Revenue Model

Company Description

Olympus Corporation manufactures and sells precision machineries and instruments worldwide. It operates through four segments: Endoscopic Solutions Business, Therapeutic Solutions Business, Scientific Solutions Business, and Others. The Endoscopic Solutions Business segment offers gastrointestinal and surgical endoscopes, endoscopy system, and repair services. The Therapeutic Solutions Business segment provides urology, gynecology, ear, nose, and throat products; endo-therapy and energy devices; and surgical single-use devices. The Scientific Solutions Business segment offers biological and industrial microscopes, industrial endoscopes and videoscopes, non-destructive testing equipment, and X-ray fluorescence (XRF) analyzers. The Others segment offers biomedical materials and orthopedic equipment. The company also offers medical devices, such as surgical microscopes, endoscope reprocessors, electrosurgical devices, and respiratory-endotherapy devices, as well as system integration and maintenance/services. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was founded in 1919 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Olympus generates revenue through a diversified model that includes the sale of medical systems, life sciences, and industrial products. The medical systems segment is a significant revenue driver, with endoscopic and surgical products leading sales, supported by ongoing maintenance and service contracts. Revenue is also derived from life science products, including microscopes and imaging systems used in laboratories and research institutions. The industrial solutions segment contributes through inspection equipment and services for manufacturing and quality control. Key partnerships with hospitals, research institutions, and industrial clients enhance its market presence and revenue streams. Additionally, Olympus invests in R&D to innovate and expand its product offerings, contributing to long-term growth and profitability.

Olympus Financial Statement Overview

Summary

Olympus demonstrates strong profitability and efficient cost management, but faces challenges in revenue growth and free cash flow generation. The balance sheet is stable with improved leverage, supporting long-term financial health.

Income Statement

Olympus shows strong gross profit margins consistently above 68%, indicating efficient cost management. However, the net profit margin has decreased to 11.8% in the TTM, reflecting reduced profitability. The revenue growth rate is negative at -2.8% TTM, signaling a potential challenge in maintaining sales momentum.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.30, indicating a stable leverage position. Return on equity is at 15.8% TTM, showing decent profitability from shareholders' investments. The equity ratio is stable, suggesting a balanced capital structure.

Cash Flow

Operating cash flow remains robust, but free cash flow has decreased significantly by 29.8% TTM, which could impact future investments. The free cash flow to net income ratio is healthy at 0.76, indicating good cash generation relative to profits.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	969.02B	997.33B	925.75B	881.92B	750.12B	730.54B
Gross Profit	662.62B	683.70B	583.63B	596.85B	571.70B	459.53B
EBITDA	218.79B	231.90B	112.10B	254.58B	209.97B	140.42B
Net Income	112.26B	117.86B	242.57B	143.43B	115.74B	12.92B
Balance Sheet
Total Assets	1.44T	1.43T	1.53T	1.51T	1.36T	1.18T
Cash, Cash Equivalents and Short-Term Investments	245.71B	252.53B	340.93B	169.33B	302.57B	217.48B
Total Debt	276.73B	229.10B	299.62B	340.06B	386.13B	355.26B
Total Liabilities	708.27B	681.09B	777.03B	867.07B	846.64B	785.54B
Stockholders Equity	732.65B	751.73B	757.19B	640.09B	510.17B	394.33B
Cash Flow
Free Cash Flow	101.37B	144.46B	-22.26B	27.87B	107.96B	64.89B
Operating Cash Flow	152.00B	190.46B	42.37B	98.49B	169.73B	124.12B
Investing Cash Flow	-67.82B	-65.47B	359.99B	-58.41B	-71.02B	-118.92B
Financing Cash Flow	-111.60B	-211.54B	-276.01B	-143.18B	-40.67B	40.80B

Olympus Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1922.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7733, the sentiment is Positive. The current price of 1922.5 is above the 20-day moving average (MA) of 1890.88, above the 50-day MA of 1843.14, and above the 200-day MA of 1913.13, indicating a bullish trend. The MACD of 28.19 indicates Negative momentum. The RSI at 55.54 is Neutral, neither overbought nor oversold. The STOCH value of 76.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7733.

Olympus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7741	―	$7.87T	38.46	21.19%	0.90%	9.89%	10.30%
7733	―	$2.07T	18.64	14.88%	1.04%	0.59%	557.87%
4543	―	¥3.67T	30.27	9.17%	1.13%	7.58%	6.74%
6869	―	$1.14T	23.83	10.48%	1.71%	5.09%	-9.10%
7747	―	$628.13B	49.29	8.67%	1.02%	11.60%	-19.38%
8086	―	¥244.24B	43.51	2.49%	2.00%	8.83%	-40.24%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Olympus Corporate Events

Olympus Corporation Updates on Share Repurchase Program

Olympus Corporation announced the status of its share repurchase program, revealing that it repurchased 4,976,300 common shares for approximately JPY 9.1 billion between September 1 and September 30, 2025. This move is part of a larger plan to repurchase up to 36 million shares, aiming to enhance shareholder value and optimize capital structure.

The most recent analyst rating on (JP:7733) stock is a Buy with a Yen2000.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Tokyo High Court Dismisses Appeal in Olympus Shareholder Lawsuit

Olympus Corporation announced that the Tokyo High Court dismissed an appeal in a shareholder’s derivative lawsuit involving claims against current and former directors and auditors. The lawsuit sought damages related to alleged failures in duty concerning agreements by a Chinese subsidiary. The court’s decision supports Olympus’s stance that the claims were unfounded, potentially reinforcing its internal control practices and decision-making processes.

The most recent analyst rating on (JP:7733) stock is a Buy with a Yen2000.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Olympus Completes Significant Share Repurchase

Olympus Corporation announced the completion of a share repurchase, acquiring 13,675,400 common shares for approximately JPY 24 billion between August 1 and August 31, 2025. This move is part of a broader strategy approved by the Board of Directors to repurchase up to 36 million shares, aiming to enhance shareholder value and optimize capital structure.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen1849.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Olympus Corp Reports Decline in Quarterly Earnings

Olympus Corporation is a leading company in the MedTech industry, specializing in gastrointestinal and surgical solutions. The company has recently released its earnings report for the first quarter of the fiscal year ending March 31, 2026, highlighting a challenging period with a notable decline in revenue and profits.

Olympus Reports Decline in Q1 Financial Performance Amid Business Adjustments

Olympus Corporation reported a significant decline in its financial performance for the three months ending June 30, 2025, with revenue and profits dropping compared to the previous year. The company’s revenue fell by 12.1%, and operating profit decreased by 39.6%, largely due to the classification of its Orthopedic Business as a discontinued operation. Despite these challenges, Olympus has revised its full-year forecast, expecting minimal revenue growth but a notable decline in profits, reflecting ongoing adjustments in its business operations.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Olympus Announces Progress in Share Repurchase Program

Olympus Corporation announced the status of its share repurchase program, having repurchased 2,114,500 common shares for approximately JPY 3.83 billion between July 28 and July 31, 2025. This move is part of a broader plan approved by the Board of Directors to repurchase up to 36 million shares, valued at a maximum of JPY 50 billion, by October 31, 2025, which is intended to enhance shareholder value and optimize capital structure.

The most recent analyst rating on (JP:7733) stock is a Buy with a Yen3300.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.